• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Open Forum Infect Dis . Sensitivity of the Elecsys Nucleocapsid Assay for the Detection of Preceding SARS-CoV-2 Infections

tetano

tetano

Editor, Senior Moderator
Open Forum Infect Dis


. 2022 Jul 26;9(8):ofac349.
doi: 10.1093/ofid/ofac349. eCollection 2022 Aug.
Sensitivity of the Elecsys Nucleocapsid Assay for the Detection of Preceding SARS-CoV-2 Infections


Brian Grunau[SUP] 1 [/SUP], Janessa Tom[SUP] 2 [/SUP], Michael Asamoah-Boaheng[SUP] 3 [/SUP], Sheila F O'Brien[SUP] 4 [/SUP], Steven J Drews[SUP] 4 [/SUP], Sadaf Sediqi[SUP] 5 [/SUP], Pascal M Lavoie[SUP] 6 [/SUP], Vilte Barakauskas[SUP] 5 [/SUP], David M Goldfarb[SUP] 5 [/SUP]



Affiliations

Abstract

Nucleocapsid serological assay sensitivity to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among vaccinees and for Omicron cases is unclear. In this prospective study, the Elecsys nucleocapsid assay was 89% sensitive in identifying SARS-CoV-2 infections 14-607 days pre-blood collection. Sensitivity was similar when comparing by vaccination status, and in Omicron (vs pre-Omicron) cases.

Keywords: COVID-19; SARS-CoV-2; antibodies; nucleocapsid; vaccine.
 
You must log in or register to reply here.
Back
Top Bottom